CLINICAL STUDY

Enterprise stent for symptomatic complex intracranial atherosclerotic stenosis: safety and efficiency

Yanhua Dong, Chao Liu, Dongdong Li, Zhen Chen,
Xiaozhen Sun, Sheng Guan *

Abstract

Purpose: To evaluate the safety and efficacy of Enterprise stent in the treatment of symptomatic complex intracranial atherosclerotic stenosis.

Methods and materials: 20 complex cases among 53 patients with symptomatic ischemic stroke who were treated with balloon angioplasty and enterprise stents in Department of Neuro-interventional Radiology, The First Affiliated Hospital of Zhengzhou University from Jan. 2014 to Dec. 2017 were retrospectively enrolled in this study. Diagnostic criteria for complex intracranial atherosclerotic stenosis were as follows: 1) intracranial atherosclerotic stenosis was ≥70% confirmed by digital subtraction angiography (DSA) using the formulas described by the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) method; 2) length of lesion was >10 mm. Basic characteristics of target lesions, technical success rate, perioperative safety, follow-up outcomes were investigated.

Results: 20 patients were enrolled in this study, including 15 males and 5 females from 44 to 70 years old with an average age of 57.20 ± 9.25. 20 lesions were treated with 20 enterprise stents. The average preoperative and postoperative residual stenosis was reduced from (77.45 ± 8.44)% to (24.89 ± 16.61)%. The successful rate of operation was 100%. Among the perioperative complications, only 1 case (5%) experienced perforating branch event. The average clinical follow-up period was 13.15 ± 11.33 months (time range: 5–38). There were no ischemic events, no bleeding events and no various causes of death during the follow-up period. 8 lesions (40.0%) underwent DSA follow-up examinations and 12 lesions (60.0%) were checked by CT angiography during the follow-up period. 3 lesions (15.0%) developed ISR without any cerebral ischemia symptoms.

Conclusion: This retrospective, single-center study suggests that enterprise stent is effective in the treatment of symptomatic complex intracranial atherosclerotic stenosis with less perioperative complications. Prospective, multicenter, randomized controlled trials are expected.

Keywords: Enterprise stent; intracranial atherosclerotic stenosis; endovascular treatment

Department of Neuro-interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

* Correspondence: Sheng Guan, Department of Neuro-interventional Radiology, The First Affiliated Hospital of Zhengzhou University, 1 Jianshe Road, Zhengzhou 450052, China, Email: gsradio@126.com

Conflict of interest: The authors declare that they have no conflict of interest.

Funding: This research did not receive a specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Ethics approval: Ethics approval was obtained from the local institutional review board.

Informed consent: Not applicable.

Provenance and peer review: Not commissioned; externally peer reviewed.
Author contributions: SG designed the study; YD, CL, DL, ZC, XS collected the related date; YD wrote the manuscript; All authors discussed and contributed to the analysis of the data.

*Journal of Interventional Medicine* 2018, Vol. 1, No. 4, pp. 234–239

INTRODUCTION

Intracranial atherosclerotic stenosis (ICAS) is one of the main causes of stroke, especially in the Asian population (1). The current guidelines for the treatment of ICAS are still antiplatelet aggregation drugs, but for moderate and severe ICAS patients with the drug treatment, the annual recurrence rate of stroke is 10–24% (2). Wingspan stents, self-expandable stents, were approved by FDA for the treatment of ICAS. However, the SAMMPRIS multicenter study was terminated early because the stroke and mortality rate in the wingspan stent group within 30 days were significantly higher than those in the drug treatment group, and the adverse events were twice as high as expected (3). There are few reports on the treatment of intracranial atherosclerotic stenosis with enterprise stents. This study reports the follow-up results of enterprise stent in the treatment of symptomatic complex intracranial atherosclerotic stenosis since 2014.

METHODS

Patient population

53 patients with symptomatic ischemic stroke were treated with enterprise stents in our department from Jan. 2014 to Dec. 2017 (27 patients with symptomatic intracranial stenosis, 21 patients with atherosclerotic intracranial large vessel occlusion and 5 patients with cerebral artery dissection). 20 lesions met the following inclusion criteria: 1) intracranial atherosclerotic stenosis was &ge;70% confirmed by DSA using the formulas described by the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) method; 2) length of lesion is \textgreater{} 10 mm; 3) cerebral infarction in the blood supply area within 90 days; 4) still with recurrent symptoms under anti-platelet aggregation therapy. Patients with any of the following were excluded: 1) total occlusive lesion; 2) non-atherosclerotic stenosis; 3) preoperative modified Rankin Scale (mRS) score is over 3; 4) acute cerebral infarction within 24 hours.

Procedures

Preoperative preparation

1) preoperative evaluation of cerebral ischemia degree by cranial CT perfusion or MR perfusion-weighted imaging, and DSA were performed to evaluate path classification [referring to LMA classification (4)], the stenosis rate, the length of lesions, the diameter of proximal and distal vessels, relationship with branch blood vessels and collateral circulation compensation. 2) antiplatelet aggregation drugs (100 mg aspirin plus 75 mg clopidogrel daily) were given before operation for at least 5 days, and thromboela-stogram was used to detect the effect of antiplatelet aggregation drugs. The patients with insufficient platelet inhibition (AA &lt; 50%, ADP &lt; 30%) were given an intensive anti-platelet aggregation drug. During the perioperative period, lipid-regulating drugs (Atto vastatin 20 mg qd or Rosuvastatin 10 mg qd) were given for at least 3 months. At the same time, drug therapy for corresponding risk factors was given.

Operation process

Patients were performed under general anesthesia, the femoral artery was punctured with modified seldinger technique, a 6F envoy guiding catheter (Cordis, USA) was introduced through a femoral sheath. The whole body heparinization was achieved by injecting with heparin sodium (1 mg/ kg) through vein. Cerebral angiography was performed prior to the treatments. The stenosis, diameter and length of the target lesion were calculated again. Referring to the diameter of the target lesion, the gateway balloon catheter (Boston Scientific, USA) was selected with 80% of the “normal” parent artery proximal to the stenosis and the length was selected to match the stenosis. With the help of 0.014 in transcend or synchro microguide wire (Stryker, USA), the gateway balloon catheter reached stenosis segment, the balloon was dilated slowly, with a final pressure of 6 atm for about 3 minutes. Withdraw the balloon catheter and feed into the select plus microcatheter (stryker, USA) along the microguide wire. Enterprise stent (Cordis, USA) was delivered through microcatheter, located accurately and released after crossing the narrow segment. If the residual stenosis rate was over 50%, the in-stent balloon expansion
was carried out. 5 minutes after the release of the stent, the anterior-posterior and lateral arteriography of the responsible artery was performed to confirm the presence of artery and its distal branches. Xper CT was performed to see whether there was hematencephalon. Successful stent placement was defined as complete coverage of the target lesion, no displacement and thrombosis in the stent, and residual stenosis was less than 50%.

**Post operation management**

After the operation, a dynamic monitoring of electrocardiogram and blood pressure was provided. We kept blood pressure to target value (10%–15% lower than basic blood pressure). A daily dose of aspirin (100 mg) and clopidogrel (75 mg) was recommended for half a year followed by only aspirin (100 mg). The risk factors, such as hypertension, diabetes mellitus and hyperlipoidemia, were given treatment.

**Follow-up and definition of in-stent restenosis**

Patients were followed up by telephone within 30 days, and mRS scale was used to evaluate prognosis (≤2, good prognosis; >2, poor prognosis). The first follow-up of DSA was 3–6 months later after the operation, followed by DSA or CTA each year. In the two-dimensional DSA image, ISR was well-defined as >50% stenosis within or immediately adjacent (within 5 mm) to the stent with >20% luminal loss.

**Statistical methods**

Statistics analysis was performed with the SPSS version 21.0 (IBM, Armonk, NY, USA). The baseline, imaging and stenting data of all patients were presented as means ± standard deviation for continuous variables and number for categorical data. Continuous variables were tested with the student t-test and Wilcoxon signed-rank test while categorical data with a Fisher exact test. Factors affecting restenosis were analyzed with the logistic regression method. The significant P value was set at <0.05.

**RESULTS**

**Patient characteristics**

From Jan.2014 to Dec. 2017, 20 patients with 20 lesions received treatment using the enterprise stent, 15 (75.0%) were men and 5 (25.0%) were women. Their mean age was 57.20 ± 9.25 years old (age range: 44–70 years old). The details of the 20 lesions included in this study are shown in Tables 1 and 2. Enterprise stent was performed within 90 days for patients with ischemic stroke. The mean stenotic vessel length was 17.46 ± 4.39 mm (length range:
Perioperative complications and follow-up results

Success rate of the operation reached 100%. There was only 1 case (5%) with distal arterial embolism which was treated with increasing fluid infusion. 20 patients were available for the clinical follow-up 5–38 (13.15 ± 11.33) months after treatment. No patient experienced recurrent TIA or stroke. Overall, 8 lesions (40.0%) underwent DSA follow-up examinations and 12 lesions (60.0%) were checked by CT angiography during the follow-up period. 3 lesions (15.0%) developed ISR without any cerebral ischemia symptoms.

DISCUSSION

The optimal treatment for symptomatic intracranial atherosclerotic stenosis (sICAS) remains controversial. The results of WASID and SAMMPRIS studies show that drug therapy can reduce the stroke recurrence rate. Intracranial stenting can also reduce the stroke recurrence rate by improving the blood flow of responsible lesions (5,6). Wingspan stent is the only self-expandable stent approved by FDA in the United States for the treatment of sICAS. But Lutsep et al. (6) shows that SAMMPRIS results cannot provide evidence to support that wingspan stent angioplasty is superior to intensive drug therapy. Clinical practice shows that the manipulation of winspan is complex, its unique delivery system may not be able to pass through the circuitous lesions and the head of the wingspan stent has lower softness, which can easily cause vascular injury. In addition, the radial support force of wingspan stent is larger and its continuous stimulation to endovascular membrane may lead to in-stent restenosis. It is reported in the literature that the rate of in-stent restenosis by wingspan can be as high as 31.2% (7). Feng et al. (8) considered that it was safer and more effective for long lesions (>15 mm) treated with enterprise stents than wingspan stents. Apollo stent (MicroPort, Shanghai) is an intracranial dedicated ball-expanding stent with stent diameter of 2.5–4.0 mm and a stent length of 8–23 mm. In 2015, the VISSIT test results did not support that the treatment of sICAS with ball-expanding stent was better than anti-platelet aggregation drugs (9). Jiang et al. (10) consider the flexibility of apollo stent delivery system was poor. For intracranial vessels with circuitous pathway and longer than 10 mm, its operation failure rate was high, and the light transmittance of stent itself was poor. It was difficult to observe the stent under X-ray after balloon dilatation. Stent shift might occur during withdrawal of guide wire.

Enterprise stents are self-expandable stents produced by Codman Company in the United States, which were expected to work with coils in the treatment of intracranial wide-necked aneurysms (11). The diameter of the stent is 4.5 mm, and the length ranges from 14 to 37 mm, which provides more choices for operators. The results of Krischek et al. (12) show that enterprise, which has a closed loop design, less radial support, and soft support conduit,
is easy to be placed under the guide wire, easy to be released, and to be located more accurately, compared with wingspan.

At present, enterprise stent therapy for sICAS is reported in few articles, showing that the restenosis rate of enterprise stent is from 3% to 24.7% (8,13-15). Vajda et al. (15) treated 189 patients with ICAD (with 209 lesions) using the enterprise stent, and had a DSA follow-up rate of 83%; they found that the in-stent restenosis rate was 24.7%, lower rate than that of wingspan (31.2%). Duffis et al. (16) considered a high sensitivity and specificity of CTA compared to DSA for the diagnosis of both any intracranial stenosis and for the diagnosis of 50% stenosis, so in our follow-up, 8 lesions (40.0%) were detected by DSA, the rest (60.0%) were checked by CTA, there was 3 (15.0%) in-stent restenosis. Wang et al. (13) considered that the large radial force of the wingspan stent could stimulate intimal hyperplasia and lead to restenosis in the stent, while enterprise was a self-expandable stent with less radial force. It can effectively reduce the rate of in-stent restenosis. At the same time, the continuous and small radial force of enterprise stent was conducive to the gradual recovery of the narrow vascular lumen.

Miao et al. (17) carried out a prospective study of targeted PTA or PTAS treatment in different types of sICAS patients. They considered that the Mori A lesions of the type I pathway were suitable for apollo stent and Mori B, C type lesions with the type III path were suitable for self-expandable stent. The Mori A lesion with a tortuous path is suitable for simple balloon dilatation with a total technical success rate of 96.3%. In this study, complex lesions were treated with balloon angioplasty and enterprise stent implantation. The technical success rate was 100%, and only 1 patient (5.0%) had ischemic cerebrovascular complications in perioperative period, which was less than 14.7% of perioperative complications reported by SAMMPRIS.

Jiang et al. (4) reported that the mortality of Mori A, B and C were 0, 0 and 25%, respectively. And the operation success rate of Access I was significantly higher than III. In this study, there are 9 (45.0%) Access I, 10 (50.0%) Access II and 1 (5.0%) Access III, and the high success rate of operation might be related to the fewer Access III.

In this study, there are 3 cases of in-stent restenosis (including 2 in-stent occlusion and 1 restenosis). The rate of restenosis was 15.0%, which was lower than wingspan’s in-stent restenosis that was registered by American multi-center enterprise in-stent. However, our study had several limitations. The patients enrolled in the study was relatively small, and the follow-up duration was not long. Besides, our study is a single-center experience, a prospective, multicenter, randomized controlled trial is required in the future.

**Conclusion**

For symptomatic intracranial atherosclerotic stenosis, especially patients with complex lesions, enterprise stent implantation is safe and effective. There is few data in our center due to strict criteria for intracranial stent. Prospective, multicenter, randomized controlled trials against optimal medical treatment are expected.

**REFERENCES**

1. Mehndiratta MM, Khan M, Mehndiratta P, et al. Stroke in Asia: geographical variations and temporal trends. J Neurol Neurosurg Psychiatry 2014; 85:1308–1312.
2. SSYLVIA Study Investigators. Stenting of symptomatic atherosclerotic lesions in the vertebral or intracranial arteries (SSYLVIA): study results. Stroke 2004; 35:1388–1392.
3. Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet 2014; 383:333–341.
4. Jiang W-J, Wang Y-J, Du B, et al. Stenting of symptomatic M1 stenosis of middle cerebral artery. Stroke 2004; 35:1375–1380.
5. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352:1305–1316.
6. Lutsep HL, Lynn MJ, Cotsonis GA, et al. Does the stenting versus aggressive medical therapy trial support stenting for subgroups with intracranial stenosis? Stroke 2015; 46:3282–3284.
7. Turk AS, Levy EI, Albuquerque FC, et al. Influence of patient age and stenosis location on wingspan in-stent restenosis. Am J Neuroradiol 2007; 29:23–27.
8. Feng Z, Duan G, Zhang P, et al. Enterprise stent for the treatment of symptomatic intracranial atherosclerotic stenosis: an initial experience of 44 patients. BMC Neurol 2015; 15:187.
9. Zaidat OO, Fitzsimmons B-F, Woodward BK, et al. Effect of a balloon-expandable intracranial stent vs medical
therapy on risk of stroke in patients with symptomatic intracranial stenosis. JAMA 2015; 313:1240–1248.

10. Jiang WJ, Xu XT, Jin M, et al. Apollo stent for symptomatic atherosclerotic intracranial stenosis: study results. AJNR Am J Neuroradiol 2007; 28:830–834.

11. Higashida RT, Halbach VV, Dowd CF, et al. Initial clinical experience with a new self-expanding nitinol stent for the treatment of intracranial cerebral aneurysms: the Cordis Enterprise stent. AJNR Am J Neuroradiol 2005; 26:1751–1756.

12. Krischek Ö, Miloslavski E, Fischer S, et al. A comparison of functional and physical properties of self-expanding intracranial stents [Neuroform3, Wingspan, Solitaire, Leo(+), Enterprise]. Minim Invasive Neurosurg 2011; 54:21–28.

13. Wang X, Wang Z, Wang C, et al. Application of the enterprise stent in atherosclerotic intracranial arterial stenosis: A series of 60 cases. Turk Neurosurg 2016; 26:69–76.

14. Vajda Z, Guthe T, Perez MA, et al. Prevention of intracranial in-stent restenoses: predilatation with a drug eluting balloon, followed by the deployment of a self-expanding stent. Cardiovasc Intervent Radiol 2013; 36:346–352.

15. Vajda Z, Schmid E, Güthe T, et al. The modified Bose method for the endovascular treatment of intracranial atherosclerotic arterial stenoses using the Enterprise stent. Neurosurgery 2012; 70:91–101.

16. Duffis EJ, Jethwa P, Gupta G, et al. Accuracy of computed tomographic angiography compared to digital subtraction angiography in the diagnosis of intracranial stenosis and its impact on clinical decision-making. J Stroke Cerebrovasc Dis 2013; 22:1013–1017.

17. Miao Z, Song L, Liebeskind DS, et al. Outcomes of tailored angioplasty and/or stenting for symptomatic intracranial atherosclerosis: a prospective cohort study after SAMMPRIS. J Neurointerv Surg 2014; 7:331–335.